Semaglutide in Early Pregnancy: Case Report and Literature Review of Outcomes
A case report and literature review of semaglutide exposure in early pregnancy documented pregnancy outcomes, contributing to the limited safety data for this common clinical scenario.
Quick Facts
What This Study Found
Case report of semaglutide early pregnancy exposure with literature review documenting pregnancy outcomes, contributing to limited but growing safety data for this increasingly common scenario.
Key Numbers
How They Did This
Case report with systematic literature review of semaglutide early pregnancy exposure and outcomes.
Why This Research Matters
Millions of women of reproductive age take semaglutide. Understanding pregnancy exposure outcomes guides risk counseling.
The Bigger Picture
As GLP-1 drug use expands in women of reproductive age, pregnancy exposure data becomes critical for informed prescribing.
What This Study Doesn't Tell Us
Case-level evidence. Cannot establish safety definitively. Reporting bias toward adverse outcomes possible.
Questions This Raises
- ?Should pregnancy testing be routine for semaglutide users?
- ?How quickly should semaglutide be stopped when pregnancy is discovered?
- ?Does the formulation (oral vs injectable) affect pregnancy risk?
Trust & Context
- Key Stat:
- Growing safety database Each case of semaglutide pregnancy exposure adds to the limited safety data guiding risk counseling for millions of women
- Evidence Grade:
- Case report with literature review — low evidence level but essential for safety database building.
- Study Age:
- Published in 2025.
- Original Title:
- Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature.
- Published In:
- Journal of gynecology obstetrics and human reproduction, 55(4), 103133 (2026)
- Authors:
- Jin, Yuan-Cheng, Wu, Yu-Hua, Ma, Xue-Song, Shi, Wen, Wu, Miao-Lian, Hu, Qing-Qing
- Database ID:
- RPEP-15388
Evidence Hierarchy
Frequently Asked Questions
Is semaglutide dangerous during pregnancy?
The data is limited but growing. This case report adds to available evidence. Current guidance is to stop semaglutide before planned pregnancy and as soon as pregnancy is discovered.
What should I do if I get pregnant on semaglutide?
Stop semaglutide immediately and contact your obstetrician. Available evidence does not suggest high risk, but the data is still limited. Your doctor can provide personalized guidance.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15388APA
Jin, Yuan-Cheng; Wu, Yu-Hua; Ma, Xue-Song; Shi, Wen; Wu, Miao-Lian; Hu, Qing-Qing. (2026). Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature.. Journal of gynecology obstetrics and human reproduction, 55(4), 103133. https://doi.org/10.1016/j.jogoh.2026.103133
MLA
Jin, Yuan-Cheng, et al. "Semaglutide exposure in early pregnancy and pregnancy outcomes: A case report and review of literature.." Journal of gynecology obstetrics and human reproduction, 2026. https://doi.org/10.1016/j.jogoh.2026.103133
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide exposure in early pregnancy and pregnancy outcom..." RPEP-15388. Retrieved from https://rethinkpeptides.com/research/jin-2026-semaglutide-exposure-in-early
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.